Get the Stockscreener App
1,131.42
0.55%
6.15
After Hours:
1123.00
-8.42
-0.74%
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,131.42, with a volume of 4.08M.
It is up +0.55% in the last 24 hours and up +14.42% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,125.27
Open:
$1142.97
24h Volume:
4.08M
Relative Volume:
1.32
Market Cap:
$1.01T
Revenue:
$72.25B
Net Income/Loss:
$25.28B
P/E Ratio:
40.73
EPS:
27.781
Net Cash Flow:
$10.37B
1W Performance:
+2.39%
1M Performance:
+14.42%
6M Performance:
+11.99%
1Y Performance:
+47.77%
1-Day Range:
$1,131.03
$1,166.29
1-Week Range:
$1,052.15
$1,166.29
52-Week Range:
$623.78
$1,166.29
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, MRK, AZN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,131.42 | 1.00T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
232.77 | 549.25B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
227.23 | 397.42B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
120.79 | 297.02B | 65.51B | 8.93B | 14.12B | 3.5532 |
AZN
Astrazeneca Plc
|
185.95 | 281.95B | 60.48B | 10.40B | 8.05B | 3.3297 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-17-26 | Downgrade | HSBC Securities | Hold → Reduce |
| Feb-25-26 | Initiated | RBC Capital Mkts | Outperform |
| Feb-20-26 | Initiated | Barclays | Overweight |
| Jan-07-26 | Resumed | UBS | Buy |
| Dec-16-25 | Upgrade | Daiwa Securities | Neutral → Buy |
| Dec-15-25 | Reiterated | BofA Securities | Buy |
| Dec-15-25 | Reiterated | Goldman | Buy |
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
What's Keeping Eli Lilly and Company In The Healthcare Spotlight? - Kalkine Media
Deal Watch: Lilly Continues Hectic Deal Stretch Via Renal-Focused Ascidian Collab - Citeline News & Insights
Eli Lilly and Novo Nordisk looking beyond US for obesity drug growth - Business Standard
Here’s Why Eli Lilly (LLY) is Among the 10 Best American Stocks to Buy and Hold for the Next Decade - Insider Monkey
Jim Cramer’s Opinion on 13 Stocks Like Eli Lilly and Boeing and Increased AI-Related Spending - Insider Monkey
Why is Eli Lilly stock rallying today? By Investing.com - Investing.com Nigeria
GLP-1 Drugs Projected to Reach $150B in Sales by 2030, Boosting LLY and NVO - GuruFocus
Eli Lilly and Co Stock (LLY) Moved Up by 3.15% on Jun 5: Facts Behind the Movement - TradingKey
Jim Cramer Details How Eli Lilly Could Defeat Competitors - Yahoo Finance
Eli Lilly (LLY) Stock Surges 4% After CVS Reverses Zepbound Coverage Decision - Blockonomi
Eli Lilly tops list of Ireland’s biggest corporate taxpayers - Business Post
Morgan Stanley reiterates Overweight on Eli Lilly stock, sees upside By Investing.com - Investing.com India
Morgan Stanley reiterates Overweight on Eli Lilly stock, sees upside - Investing.com
Barclays Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,400 - 富途牛牛
CVS Health Just Announced Fantastic News to Eli Lilly Stock Investors - AOL.com
The Zacks Analyst Blog Highlights Berkshire, Eli Lilly, Walmart, Universal Health Realty Income and Utah - Yahoo Finance Singapore
AriBio joins Lilly TuneLab to advance AI-driven neuroscience research - koreabiomed.com
HIMS Stock Slides Overnight: CEO Sees Healthcare Potential In Anthropic's AI Leap As Lilly, WeightWatchers Turn Up The Heat - Stocktwits
Lilly and Novo Now Look Beyond US for Obesity Drug Growth - Bloomberg.com
Lilly and Novo now look beyond US for obesity drug growth - BusinessLine
Eli Lilly and Co (LLY) Shares Surge 4.3% -- What GF Score of 98 Tells Investors - GuruFocus
Analyst Ratings | Citi: Reiterates “Buy” rating on Eli Lilly and Co, saying market concerns over side effects of experimental weight-loss drug are "overblown" - 富途牛牛
Upper Macungie advances Eli Lilly plan - WFMZ.com
Eli Lilly's 'Overbroad' Weight Drug TM Deal Rejected - Law360
Gilead, Merck, Eli Lilly lead $106B biopharma takeover wave in 2026 - MSN
Aribio joins Lilly TuneLab to boost AI-driven CNS drug developmentCHOSUNBIZ - Chosunbiz
Aribio Joins Lilly's AI Drug Discovery Platform - 아시아경제
Gilead, Merck, Eli Lilly Lead $106B Biopharma Takeover Wave In 2026 - Stocktwits
Eli Lilly, IBD stock of the day, flashes two buy signals - MSN
Eli Lilly, IBD Stock Of The Day, Flashes Two Buy Signals - Investor's Business Daily
Top Analyst Reports for Berkshire Hathaway, Eli Lilly & Walmart - Yahoo Finance
Jim Cramer’s 5 Stock Calls, Including Alphabet and Eli Lilly, and Possible Opportunities - Insider Monkey
Stock Market Today, June 4: Broadcom Drags on Nasdaq at Midday - The Motley Fool
Weight Watchers Broadens GLP-1 Reach As Eli Lilly Pursues New Kidney Disease TherapiesEli Lilly (NYSE - Benzinga
Lilly Gateway Labs incubator in Center City gets its first tenant - The Business Journals
Why is Eli Lilly stock surging today? - Investing.com
Eli Lilly Sees More Dealmaking Ahead as Management Looks To Leverage Its GLP-1 Success - The Motley Fool
Eli Lilly and Co Stock (LLY) Moved Up by 3.56% on Jun 4: What Signal Does It Send? - TradingKey
Eli Lilly's $1 Trillion Milestone and Growth Strategy in 2026News and Statistics - IndexBox
Pharma's New Playbook: How Lilly and Sesame Are Bypassing Insurance - BriefGlance
Weight Watchers connects with Eli Lilly’s LillyDirect platform - Investing.com
3 Reasons Eli Lilly Remains a Buy - The Motley Fool
US pharma giant Eli Lilly is very unhappy with Germany; CEO calls its planned healthcare reform: Terrible - The Times of India
Eli Lilly, Dixie Cup developers are among those seeking tax benefits in Lehigh Valley. Here’s why. - The Morning Call
Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup - Forbes
Forget Weight Loss Drugs: Here Is Another Reason to Buy Eli Lilly Stock - The Motley Fool
Eli Lilly (LLY) Stock Analysis: Diversification Strategy and Vaccine Deals in 2026News and Statistics - IndexBox
Moderna Outshines Pharma Giants Lilly, Merck and Pfizer With 43% Year-to-Date Surge - NAI500
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating - 富途牛牛
Eli Lilly Weight Loss Boom Reshapes Healthcare Growth Story - Kalkine Media
Law Firm Asks US to Investigate Eli Lilly’s Drug Discount Policy - Bloomberg Law News
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.02%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):